KA/EN
Register
Medicines reference
Search
Search
Active substance

Flumethrin

Favourites

Pyrethroid insecticide and acaricide. Registered in Georgia: 8 veterinary products. Forms: pour-on, spot-on, topical (unspecified).

Cat: Allowed by the label
Authorised for cats by the label (a collar, with imidacloprid), kittens from 10 weeks.
Source: Seresto Foresto 1.25 g + 0.56 g collar for cats, SPC 3.1 „Cats", kittens from 10 weeks (UPD 700000105524) · UPD ↗
 Species safety: cats →
Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

Known Contraindications

  • Critical
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients. Nepoužívat v případech přecitlivělosti na léčivé látky nebo na některou z pomocných látek.
    Sources: VMD SPC · USKVBL PIL · VMD
  • Critical (Dog)
    Do not treat puppies less than 7 weeks of age. Nepoužívat u štěňat do 3 měsíců
    Sources: VMD SPC · USKVBL PIL · VMD
  • Critical (Cat)
    Do not treat kittens less than 10 weeks of age.
    Sources: VMD SPC · VMD
  • Warning
    The safety of the veterinary medicinal product has not been established in target animals during pregnancy and lactation. Pregnancy and lactation: The use is not recommended during pregnancy and lactation. Laboratory studies with either flumethrin or imidacloprid in rats and rabbits showed no teratogenic, or foetotoxic effects. Nebyla stanovena bezpečnost veterinárního léčivého přípravku pro použití během březosti.
    Sources: VMD SPC · USKVBL PIL · VMD
  • Warning
    The use is not recommended during pregnancy and lactation.
    Sources: VMD SPC · VMD
  • Caution
    Organophosphates slow or prevent pyrethroid breakdown and can increase flumethrin toxicity: avoid combining with organophosphate ectoparasiticides.
Latin name
Flumethrin
Georgian name
ფლუმეტრინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
8 of 9 forms
Products
Flutron, Kiltix, Seresto, Soltif Home
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration9

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Flutron 10 mg/ml, Pour-on

flumethrin 10 mg/ml, pour-on solution
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
5.6/10
Weak evidence support
vetman assessment

Flutron

10 mg/ml, flumethrin 10 mg/ml, pour-on solution
Assessed clinical scopeDog · Label-concordant topical treatment/control of canine Demodex infestation · On the skin
Care settingVeterinary-supervised external application with serial clinical and microscopic reassessment
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: No longer listed · № 000142, 000143, 001274 · Verified on 22 Oct 2026

A verifiable but weakly evidenced labelled option for canine Demodex. Its single 1 ml/10 kg application is simple, yet no independent outcome study, dog repeat schedule or remission endpoint was found, modern consensus favours well-studied alternatives, and the Georgian registration had expired by review.

Regulatory and scientific credibility6.0/10

The exact strength, manufacturer, dog dose and 2025 ministry-hosted Bosnia authorisation are verifiable. Scientific credibility is limited by absent exact-product outcome data, no dog repeat protocol and expiry of all reviewed Georgian registration records two days before assessment.

Clinical efficacy4.0/10

The exact label claims canine Demodex control, but no independent Flutron/flumethrin-pour-on canine trial was identified and the label gives no repeat course or remission endpoint. Current consensus supports serial scrapings and well-studied isoxazolines, not flumethrin pour-on.

Safety and tolerability6.0/10

One correct external dose has a simple label safety profile, but the claim that no adverse events were reported has no denominator. Pyrethroid hypersensitivity, skin irritation, licking/ocular exposure, organophosphate-amplified toxicity, absent antidote and sparse dog reproductive data remain material.

Clinical practicality7.0/10

The weight-based pour-on is quick and needs no equipment beyond accurate volume measurement. Practical value is reduced by large 100/500 ml packs for most dogs and, critically, no dog-specific repeat interval or full-course endpoint, so serial scrapings and a separate evidence-based continuation plan are still required.

Full-course cost-effectiveness-

Current Georgian pack price and comparable complete-course costs were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Dogs only for this assessment. Cats are not an exact-label target and have no established Flutron dose; do not infer feline safety from flumethrin collars or transfer the canine pour-on dose.
  • Exact dog dose: 1 ml/10 kg (0.1 ml/kg; flumethrin 1 mg/kg) externally on affected areas or along the spine from nose to tail base. Measure by body weight and do not saturate the coat or increase the dose empirically.
  • The exact dog subsection gives no repeat interval, course length, maximum field or remission endpoint. A later general external-parasite paragraph mentions 4–8-week reapplication, but it does not expressly apply that interval to canine Demodex; do not convert it into a dog-specific schedule.
  • Demodicosis requires classification and monitoring: confirm mites, distinguish localised from generalised disease, investigate underlying immunosuppression in adult onset and perform serial deep scrapings/trichograms until microscopic remission. One application is not proof of cure.
  • Current consensus favours well-studied isoxazolines for generalised canine demodicosis. If mite counts and lesions do not improve, use an evidence-based protocol rather than repeating Flutron on an unsourced interval.
  • External use only. Avoid eyes, mouth, mucosa, ingestion and markedly damaged skin; prevent licking and contact with other animals until dry. Stop and wash for substantial irritation, tremor, hypersalivation, vomiting, ataxia or another systemic/neurological sign.
  • Do not combine with an organophosphate ectoparasiticide: organophosphates can impair pyrethroid breakdown and increase mammalian toxicity. The label's efficacy statement about other pyrethroids is not permission to stack pyrethroids without a verified safety rationale.
  • No specific antidote exists. For overdose or poisoning, minimise exposure, wash contaminated skin/eyes with abundant water and provide prompt veterinary symptomatic/supportive treatment.
  • Pregnancy evidence is limited to “no complications reported,” not a controlled reproductive study. Use in breeding, pregnant or lactating dogs only after explicit benefit–risk assessment.
  • Environmental and handler protection: flumethrin is highly hazardous to aquatic life. Keep product and wash-off out of drains, rubbish and waterways; wear gloves for repeated handling, do not eat/drink/smoke during application, wash hands and store closed at 10–25 °C away from food and light.
Assessment sources
  1. FMPVS Flutron exact2025
  2. Teknovet Flutron exact2026
  3. NFA Flutron exact2026
  4. WAVD Demodex 20202020
  5. Merck mange 20262026
  6. CAPC Demodex2026
  7. UPD Actifend control2026
  8. EPA Seresto control2014
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Flumethrin10 mg/ml
Formulation Type
Pour-on
Administration route
On the skin
Manufacturer
Teknovet · Türkiye
Registration
Georgia No longer listed
Was registered; not in the current register
Veterinary (National Food Agency)
In the register: ფლუტრონი
№ 000142, 000143, 001274
Verified on: 22 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Dogs, Demodex only: 1 ml/10 kg (0.1 ml/kg; 1 mg/kg flumethrin) externally on affected areas or along the spine from nose to tail base. The exact dog subsection gives no repeat interval, course length or microscopic endpoint. A later general external-parasite paragraph mentions 4–8-week reapplication but does not expressly apply it to canine Demodex. Cats: not a target species and no dose is established.

Kiltix 1.25 g/0.28 g, Topical (unspecified)

propoxur 1.25 g + flumethrin 0.28 g, collar 38 cm for small dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Kiltix

1.25 g/0.28 g, propoxur 1.25 g + flumethrin 0.28 g, collar 38 cm for small dogs
Assessed clinical scopeDog · Full canine label: control of Ixodes ricinus and Rhipicephalus sanguineus ticks and Ctenocephalides canis/felis fleas for up to seven months with continuous collar wear · On the skin
Care settingContinuous home collar wear after ectoparasite-risk assessment; select the exact dog-size collar, allow two-finger clearance, inspect the fit and skin, and manage bathing and water exposure
vetman score 7.8/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 322-11, 33-11 · Verified on 15 Oct 2026

A useful long-duration canine collar for the labelled flea and tick role, with direct evidence extending to roughly six or seven months. Its older evidence base and propoxur-related patient, household and environmental restrictions keep it below newer best-documented long-acting options.

Regulatory and scientific credibility8.5/10

Both exact collar lengths are registered in Georgia and the formulation has current regulator-hosted product information, a transparent long authorisation history and direct product-family efficacy studies. The independent evidence base is nevertheless old and limited in scale.

Clinical efficacy7.8/10

The label supports flea and tick control for up to seven months. A 30-dog controlled study found over 95% immediate and over 93% residual Rhipicephalus efficacy through day 170, while a small 17-dog study supported prolonged flea and tick activity; broader modern comparative evidence is sparse.

Safety and tolerability6.8/10

Target-animal studies and regulator information support low clinically important absorption and uncommon label adverse reactions under correct use. The propoxur component adds meaningful carbamate restrictions, ingestion toxicity, reproductive uncertainty in the exact leaflet and substantial handler and environmental precautions.

Clinical practicality8.1/10

One correctly fitted collar provides continuous protection for up to seven months and begins acting within 24 hours. Continuous wear, regular fit and skin checks, removal for bathing or swimming, prevention of chewing and household-contact precautions create a manageable but material home-care burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • For dogs only. Do not use in puppies under three months, animals with skin injury, sick or convalescent dogs, or animals hypersensitive to propoxur, flumethrin or an excipient.
  • Do not use in animals with mechanical gastrointestinal or urinary obstruction, bronchial asthma, other pulmonary disease or cardiovascular disease because carbamates can contract smooth muscle.
  • Concurrent use of another acaricide or insecticide is not recommended.
  • Safety during pregnancy has not been established in the exact current leaflet; use only after an individual benefit-risk assessment.
  • Prevent chewing or ingestion. Carbamate poisoning can cause salivation, miosis, vomiting or diarrhoea; remove the collar and provide urgent veterinary treatment, with atropine identified by the leaflet as the antidote.
  • Check fit and skin, especially during the first days. Very rare local, systemic, gastrointestinal or behavioural reactions are reported; remove the collar and assess the dog if signs develop.
  • Activity begins within 24 hours and depends on continuous wear, coat condition, activity and infestation pressure. Occasional attached ticks may still be seen and can take up to three days to die.
  • Wash hands after fitting, avoid prolonged contact with the collar and treated coat, and keep children from touching, playing with or mouthing it. A collared dog should not sleep in the owner's bed, especially with children.
  • Remove the collar for bathing or swimming. The product is highly toxic to aquatic organisms, birds and bees; keep it out of watercourses and dispose of the cut-off length safely.
Assessment sources
  1. ÚSKVBL leaflet 20252025
  2. AEMPS Kiltix SPC2026
  3. Kiltix experimental tick study2003
  4. Kiltix flea and tick study1998
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Propoxur1.25 g Flumethrin0.28 g
Formulation Type
Topical (unspecified)
Administration route
On the skin
Manufacturer
Elanco · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კილტიქსი საყელო პატარა ზომის ძაღლებისთვის 1.25გ + 0,28გ
№ 322-11, 33-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Kiltix 4.5 g/1.013 g, Topical (unspecified)

propoxur 4.5 g + flumethrin 1.013 g, collar 70 cm for large dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.8/10
Good
vetman assessment

Kiltix

4.5 g/1.013 g, propoxur 4.5 g + flumethrin 1.013 g, collar 70 cm for large dogs
Assessed clinical scopeDog · Full canine label: control of Ixodes ricinus and Rhipicephalus sanguineus ticks and Ctenocephalides canis/felis fleas for up to seven months with continuous collar wear · On the skin
Care settingContinuous home collar wear after ectoparasite-risk assessment; select the exact dog-size collar, allow two-finger clearance, inspect the fit and skin, and manage bathing and water exposure
vetman score 7.8/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 319-11, 33-11 · Verified on 15 Oct 2026

A useful long-duration canine collar for the labelled flea and tick role, with direct evidence extending to roughly six or seven months. Its older evidence base and propoxur-related patient, household and environmental restrictions keep it below newer best-documented long-acting options.

Regulatory and scientific credibility8.5/10

Both exact collar lengths are registered in Georgia and the formulation has current regulator-hosted product information, a transparent long authorisation history and direct product-family efficacy studies. The independent evidence base is nevertheless old and limited in scale.

Clinical efficacy7.8/10

The label supports flea and tick control for up to seven months. A 30-dog controlled study found over 95% immediate and over 93% residual Rhipicephalus efficacy through day 170, while a small 17-dog study supported prolonged flea and tick activity; broader modern comparative evidence is sparse.

Safety and tolerability6.8/10

Target-animal studies and regulator information support low clinically important absorption and uncommon label adverse reactions under correct use. The propoxur component adds meaningful carbamate restrictions, ingestion toxicity, reproductive uncertainty in the exact leaflet and substantial handler and environmental precautions.

Clinical practicality8.1/10

One correctly fitted collar provides continuous protection for up to seven months and begins acting within 24 hours. Continuous wear, regular fit and skin checks, removal for bathing or swimming, prevention of chewing and household-contact precautions create a manageable but material home-care burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • For dogs only. Do not use in puppies under three months, animals with skin injury, sick or convalescent dogs, or animals hypersensitive to propoxur, flumethrin or an excipient.
  • Do not use in animals with mechanical gastrointestinal or urinary obstruction, bronchial asthma, other pulmonary disease or cardiovascular disease because carbamates can contract smooth muscle.
  • Concurrent use of another acaricide or insecticide is not recommended.
  • Safety during pregnancy has not been established in the exact current leaflet; use only after an individual benefit-risk assessment.
  • Prevent chewing or ingestion. Carbamate poisoning can cause salivation, miosis, vomiting or diarrhoea; remove the collar and provide urgent veterinary treatment, with atropine identified by the leaflet as the antidote.
  • Check fit and skin, especially during the first days. Very rare local, systemic, gastrointestinal or behavioural reactions are reported; remove the collar and assess the dog if signs develop.
  • Activity begins within 24 hours and depends on continuous wear, coat condition, activity and infestation pressure. Occasional attached ticks may still be seen and can take up to three days to die.
  • Wash hands after fitting, avoid prolonged contact with the collar and treated coat, and keep children from touching, playing with or mouthing it. A collared dog should not sleep in the owner's bed, especially with children.
  • Remove the collar for bathing or swimming. The product is highly toxic to aquatic organisms, birds and bees; keep it out of watercourses and dispose of the cut-off length safely.
Assessment sources
  1. ÚSKVBL leaflet 20252025
  2. AEMPS Kiltix SPC2026
  3. Kiltix experimental tick study2003
  4. Kiltix flea and tick study1998
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Propoxur4.5 g Flumethrin1.013 g
Formulation Type
Topical (unspecified)
Administration route
On the skin
Manufacturer
Elanco · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: კილტიქსი საყელო დიდი ზომის ძაღლებისთვის 4.5გ + 1,013გ
№ 319-11, 33-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Seresto 1.25 g + 0.56 g, Topical (unspecified)

imidacloprid 1.25 g + flumethrin 0.56 g, collar 38 cm for cats and dogs up to 8 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full canine label: 7-8 month flea and tick control, tick repellency, flea-larval and biting-louse control, and labelled indirect reduction of selected pathogen transmission
8.4/10
Very good
vetman assessment

Seresto

1.25 g + 0.56 g, imidacloprid 1.25 g + flumethrin 0.56 g, collar 38 cm for cats and dogs up to 8 kg
Assessed clinical scopeDog · Full canine label: 7-8 month flea and tick control, tick repellency, flea-larval and biting-louse control, and labelled indirect reduction of selected pathogen transmission · On the skin
Care settingContinuous collar wear after exact species/weight selection, correct two-finger fitting and regular skin, fit and release-mechanism checks
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 157-11 · Verified on 21 Oct 2026

A highly effective and unusually convenient long-duration canine ectoparasite option with strong direct evidence. Its score is moderated by collar-mechanics risk and pharmacovigilance signals that require correct fitting, monitoring and prompt removal if symptoms occur.

Regulatory and scientific credibility9.0/10

The exact collars are currently registered in Georgia and retain current UK VMD product information, long regulatory histories and substantial product-specific clinical and pharmacovigilance evidence.

Clinical efficacy9.0/10

Large controlled and multicentre field programmes show sustained high flea and tick efficacy over 7-8 months, repellent tick activity and species-specific ancillary benefits; protection is not absolute and may begin more slowly against an established tick burden.

Safety and tolerability7.0/10

Field trials found mainly minor local reactions, but current labels and the EPA incident review require active monitoring for skin, gastrointestinal or neurologic signs and immediate collar removal if adverse effects occur. Mechanical entrapment, choking or trauma is a distinct collar risk; pregnancy/lactation use is not recommended.

Clinical practicality9.0/10

One correctly fitted, water-resistant collar provides continuous long-duration protection with no monthly redosing, but fit, skin and release function must be checked, especially in growing or outdoor animals.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fit to allow two fingers beneath the collar and check frequently. Remove immediately if the collar catches, breathing or swallowing is affected, or any adverse reaction occurs; verify that the release mechanism is free to function.
  • During the first days, monitor for pruritus, erythema, hair loss or other local reaction; also watch for gastrointestinal or neurologic signs. Remove the collar and seek veterinary advice if clinically relevant signs occur.
  • Use the exact collar for species and weight: the 70 cm collar is only for dogs over 8 kg; the 38 cm collar is for cats or dogs up to 8 kg. Do not treat puppies under 7 weeks or kittens under 10 weeks.
  • Use during pregnancy or lactation is not recommended. Do not use in known hypersensitivity to either active substance or an excipient.
  • The collar reduces tick attachment and selected pathogen transmission but does not provide absolute protection; attached ticks may still be found and disease cannot be completely excluded.
  • Prevent chewing or ingestion of the collar, wash hands after fitting and keep the pouch, remnants and collar away from children and watercourses.
Assessment sources
  1. VMD Seresto dogs ≤8 kg 20262026
  2. Seresto European field studies2012
  3. Seresto canine controlled studies2012
  4. EPA Seresto incident review2023
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full feline label: 7-8 month flea and tick control, tick repellency, flea-larval suppression and labelled indirect reduction of selected pathogen transmission
8.3/10
Very good
vetman assessment

Seresto

1.25 g + 0.56 g, imidacloprid 1.25 g + flumethrin 0.56 g, collar 38 cm for cats and dogs up to 8 kg
Assessed clinical scopeCat · Full feline label: 7-8 month flea and tick control, tick repellency, flea-larval suppression and labelled indirect reduction of selected pathogen transmission · On the skin
Care settingContinuous collar wear after exact species/weight selection, correct two-finger fitting and regular skin, fit and release-mechanism checks
vetman score 8.3/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 157-11 · Verified on 21 Oct 2026

A highly effective and unusually convenient long-duration feline ectoparasite option with strong direct evidence. Its score is moderated by real collar-mechanics risk, pharmacovigilance signals requiring prompt removal if symptoms occur, and lack of recommended pregnancy/lactation use.

Regulatory and scientific credibility9.0/10

The exact collars are currently registered in Georgia and retain current UK VMD product information, long regulatory histories and substantial product-specific clinical and pharmacovigilance evidence.

Clinical efficacy9.0/10

Large controlled and multicentre field programmes show sustained high flea and tick efficacy over 7-8 months, repellent tick activity and species-specific ancillary benefits; protection is not absolute and may begin more slowly against an established tick burden.

Safety and tolerability6.5/10

Field trials found mainly minor local reactions, but current labels and the EPA incident review require active monitoring for skin, gastrointestinal or neurologic signs and immediate collar removal if adverse effects occur. Mechanical entrapment, choking or trauma is a distinct collar risk; pregnancy/lactation use is not recommended.

Clinical practicality9.0/10

One correctly fitted, water-resistant collar provides continuous long-duration protection with no monthly redosing, but fit, skin and release function must be checked, especially in growing or outdoor animals.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fit to allow two fingers beneath the collar and check frequently. Remove immediately if the collar catches, breathing or swallowing is affected, or any adverse reaction occurs; verify that the release mechanism is free to function.
  • During the first days, monitor for pruritus, erythema, hair loss or other local reaction; also watch for gastrointestinal or neurologic signs. Remove the collar and seek veterinary advice if clinically relevant signs occur.
  • Use the exact collar for species and weight: the 70 cm collar is only for dogs over 8 kg; the 38 cm collar is for cats or dogs up to 8 kg. Do not treat puppies under 7 weeks or kittens under 10 weeks.
  • Use during pregnancy or lactation is not recommended. Do not use in known hypersensitivity to either active substance or an excipient.
  • The collar reduces tick attachment and selected pathogen transmission but does not provide absolute protection; attached ticks may still be found and disease cannot be completely excluded.
  • Prevent chewing or ingestion of the collar, wash hands after fitting and keep the pouch, remnants and collar away from children and watercourses.
Assessment sources
  1. VMD SPC 20252025
  2. Seresto European field studies2012
  3. EPA Seresto incident review2023
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Imidacloprid1.25 g Flumethrin0.56 g
Formulation Type
Topical (unspecified)
Administration route
On the skin
Manufacturer (register)
KVP Pharma + Veterinar Produkte GmbH, Germany
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 278, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ფორესტო 1.25 გ + 0.56 გ საყელო 8 კგ-მდე ძაღლებისა და კატებისათვის
№ 157-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ EPA 11556-155
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Seresto 4.50 g + 2.03 g, Topical (unspecified)

imidacloprid 4.5 g + flumethrin 2.03 g, collar 70 cm for dogs over 8 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Seresto

4.50 g + 2.03 g, imidacloprid 4.5 g + flumethrin 2.03 g, collar 70 cm for dogs over 8 kg
Assessed clinical scopeDog · Full canine label: 7-8 month flea and tick control, tick repellency, flea-larval and biting-louse control, and labelled indirect reduction of selected pathogen transmission · On the skin
Care settingContinuous collar wear after exact species/weight selection, correct two-finger fitting and regular skin, fit and release-mechanism checks
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 156-11 · Verified on 21 Oct 2026

A highly effective and unusually convenient long-duration canine ectoparasite option with strong direct evidence. Its score is moderated by collar-mechanics risk and pharmacovigilance signals that require correct fitting, monitoring and prompt removal if symptoms occur.

Regulatory and scientific credibility9.0/10

The exact collars are currently registered in Georgia and retain current UK VMD product information, long regulatory histories and substantial product-specific clinical and pharmacovigilance evidence.

Clinical efficacy9.0/10

Large controlled and multicentre field programmes show sustained high flea and tick efficacy over 7-8 months, repellent tick activity and species-specific ancillary benefits; protection is not absolute and may begin more slowly against an established tick burden.

Safety and tolerability7.0/10

Field trials found mainly minor local reactions, but current labels and the EPA incident review require active monitoring for skin, gastrointestinal or neurologic signs and immediate collar removal if adverse effects occur. Mechanical entrapment, choking or trauma is a distinct collar risk; pregnancy/lactation use is not recommended.

Clinical practicality9.0/10

One correctly fitted, water-resistant collar provides continuous long-duration protection with no monthly redosing, but fit, skin and release function must be checked, especially in growing or outdoor animals.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fit to allow two fingers beneath the collar and check frequently. Remove immediately if the collar catches, breathing or swallowing is affected, or any adverse reaction occurs; verify that the release mechanism is free to function.
  • During the first days, monitor for pruritus, erythema, hair loss or other local reaction; also watch for gastrointestinal or neurologic signs. Remove the collar and seek veterinary advice if clinically relevant signs occur.
  • Use the exact collar for species and weight: the 70 cm collar is only for dogs over 8 kg; the 38 cm collar is for cats or dogs up to 8 kg. Do not treat puppies under 7 weeks or kittens under 10 weeks.
  • Use during pregnancy or lactation is not recommended. Do not use in known hypersensitivity to either active substance or an excipient.
  • The collar reduces tick attachment and selected pathogen transmission but does not provide absolute protection; attached ticks may still be found and disease cannot be completely excluded.
  • Prevent chewing or ingestion of the collar, wash hands after fitting and keep the pouch, remnants and collar away from children and watercourses.
Assessment sources
  1. VMD SPC 20252025
  2. Seresto European field studies2012
  3. Seresto canine controlled studies2012
  4. EPA Seresto incident review2023
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Imidacloprid4.5 g Flumethrin2.03 g
Formulation Type
Topical (unspecified)
Administration route
On the skin
Manufacturer (register)
KVP Pharma + Veterinar Produkte GmbH, Germany
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 277, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ფორესტო 4.50 გ + 2.03 გ საყელო 8 კგ-ზე მძიმე ძაღლებისათვის
№ 156-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ EPA 11556-155
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Soltif Home 15%/0.9%, Spot-on

0.4 ml spot-on for dogs 1.5-7 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
4.9/10
Weak evidence support
vetman assessment

Soltif Home

15%/0.9%, 0.4 ml spot-on for dogs 1.5-7 kg
Assessed clinical scopeDog · Labelled monthly topical control of fleas and ticks in dogs within the exact presentation weight band · On the skin
Care settingVeterinary-selected home spot-on use after parasite and patient assessment, with response review when infestation persists
vetman score 4.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 235-11 · Verified on 22 Oct 2026

A locally registered dog-only spot-on with convenient monthly use, but no independent exact-product efficacy study or transparent public dossier. It is a weak-evidence option that should be used only in the exact weight band, with response reassessment and strict protection of cats from direct or wet-coat exposure.

Regulatory and scientific credibility5.5/10

The exact presentation is actively registered in Georgia and current manufacturer material verifies the formulation, weight band and monthly label. However, no regulator-hosted SPC, EMA/FDA-style public assessment or transparent full dossier for this exact dinotefuran/flumethrin spot-on was found.

Clinical efficacy3.5/10

The manufacturer claims 30-day flea and tick protection, but no independent controlled study of this exact 15% dinotefuran plus 0.9% flumethrin spot-on was found. Studies and guidelines support the individual actives or different collars and combinations; they do not validate this formulation, dose distribution or every claim.

Safety and tolerability4.5/10

Dog tolerability data for the exact formulation and repeated use are not publicly available. Pyrethroids generally have a wider margin in dogs than cats, but local and neurologic reactions and ingestion remain possible; a retrospective feline toxicosis series specifically included two Soltif exposures, making species separation essential.

Clinical practicality7.0/10

A whole monthly weight-banded pipette is simple to apply. Correct weight selection, direct placement on dry intact skin where the dog cannot lick, separation from other animals until dry and the 72-hour bathing restriction remain meaningful adherence requirements.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Dog-only product: never apply to a cat. Keep cats from grooming or contacting the treated dog until the application site is completely dry; Soltif exposure has been recorded in hospitalised feline pyrethroid-toxicosis cases.
  • Do not use in puppies younger than 8 weeks or in an animal with known hypersensitivity to an ingredient.
  • Weigh the dog and use only the presentation matching its labelled weight band; boundary weights require deliberate selection rather than estimation.
  • Apply the entire pipette directly to dry intact skin between the shoulder blades where the dog cannot lick. Separate treated animals until dry.
  • Monitor for local irritation, salivation, vomiting, depression, ataxia, tremor, twitching or seizures. If exposure or neurologic signs occur, prevent further licking, wash off when appropriate and seek urgent veterinary advice.
  • Do not layer with another flea/tick pesticide unless a veterinarian has reviewed the active ingredients, intervals and cumulative neurotoxicity.
  • Do not bathe or shampoo the dog for 72 hours after application. Frequent water exposure may reduce topical persistence; reassess rather than shortening the interval without evidence.
  • No independent controlled trial of the exact 15% dinotefuran plus 0.9% flumethrin spot-on was found. Ingredient and other-formulation studies cannot establish this product’s full 30-day performance.
  • Ectoparasiticides may harm aquatic organisms. Prevent the product, empty pipette and recently treated dog from contaminating surface water; dispose of packaging responsibly.
Assessment sources
  1. Solano Soltif Home2026
  2. Georgia NFA register 20262026
  3. ESCCAP ectoparasite guideline2024
  4. CAPC flea guideline2026
  5. EMA Vectra 3D EPAR2024
  6. Comparative ectoparasiticide study2012
  7. Feline pyrethroid toxicosis2020
  8. EMA ectoparasiticide environment 20232023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dinotefuran15 % Flumethrin0.9 %
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Solano Ltd · Israel
Manufacturer (register)
Solano Ltd, Israel
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 890, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 28 May 2028
Veterinary (National Food Agency)
In the register: სოლტიფ ჰოუმი - დასაწვეთებელი ხსნარი ლეკვებისა და ძალიან პატარა ზომის ძაღლებისათვის 1.5-7კგ (XS/P)
№ 235-11
Verified on: 22 Oct 2026
Controlled in Georgia
Unknown

Soltif Home 15%/0.9%, Spot-on

1.4 ml spot-on for dogs 7-15 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
4.9/10
Weak evidence support
vetman assessment

Soltif Home

15%/0.9%, 1.4 ml spot-on for dogs 7-15 kg
Assessed clinical scopeDog · Labelled monthly topical control of fleas and ticks in dogs within the exact presentation weight band · On the skin
Care settingVeterinary-selected home spot-on use after parasite and patient assessment, with response review when infestation persists
vetman score 4.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 236-11 · Verified on 22 Oct 2026

A locally registered dog-only spot-on with convenient monthly use, but no independent exact-product efficacy study or transparent public dossier. It is a weak-evidence option that should be used only in the exact weight band, with response reassessment and strict protection of cats from direct or wet-coat exposure.

Regulatory and scientific credibility5.5/10

The exact presentation is actively registered in Georgia and current manufacturer material verifies the formulation, weight band and monthly label. However, no regulator-hosted SPC, EMA/FDA-style public assessment or transparent full dossier for this exact dinotefuran/flumethrin spot-on was found.

Clinical efficacy3.5/10

The manufacturer claims 30-day flea and tick protection, but no independent controlled study of this exact 15% dinotefuran plus 0.9% flumethrin spot-on was found. Studies and guidelines support the individual actives or different collars and combinations; they do not validate this formulation, dose distribution or every claim.

Safety and tolerability4.5/10

Dog tolerability data for the exact formulation and repeated use are not publicly available. Pyrethroids generally have a wider margin in dogs than cats, but local and neurologic reactions and ingestion remain possible; a retrospective feline toxicosis series specifically included two Soltif exposures, making species separation essential.

Clinical practicality7.0/10

A whole monthly weight-banded pipette is simple to apply. Correct weight selection, direct placement on dry intact skin where the dog cannot lick, separation from other animals until dry and the 72-hour bathing restriction remain meaningful adherence requirements.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Dog-only product: never apply to a cat. Keep cats from grooming or contacting the treated dog until the application site is completely dry; Soltif exposure has been recorded in hospitalised feline pyrethroid-toxicosis cases.
  • Do not use in puppies younger than 8 weeks or in an animal with known hypersensitivity to an ingredient.
  • Weigh the dog and use only the presentation matching its labelled weight band; boundary weights require deliberate selection rather than estimation.
  • Apply the entire pipette directly to dry intact skin between the shoulder blades where the dog cannot lick. Separate treated animals until dry.
  • Monitor for local irritation, salivation, vomiting, depression, ataxia, tremor, twitching or seizures. If exposure or neurologic signs occur, prevent further licking, wash off when appropriate and seek urgent veterinary advice.
  • Do not layer with another flea/tick pesticide unless a veterinarian has reviewed the active ingredients, intervals and cumulative neurotoxicity.
  • Do not bathe or shampoo the dog for 72 hours after application. Frequent water exposure may reduce topical persistence; reassess rather than shortening the interval without evidence.
  • No independent controlled trial of the exact 15% dinotefuran plus 0.9% flumethrin spot-on was found. Ingredient and other-formulation studies cannot establish this product’s full 30-day performance.
  • Ectoparasiticides may harm aquatic organisms. Prevent the product, empty pipette and recently treated dog from contaminating surface water; dispose of packaging responsibly.
Assessment sources
  1. Solano Soltif Home2026
  2. Georgia NFA register 20262026
  3. ESCCAP ectoparasite guideline2024
  4. CAPC flea guideline2026
  5. EMA Vectra 3D EPAR2024
  6. Comparative ectoparasiticide study2012
  7. Feline pyrethroid toxicosis2020
  8. EMA ectoparasiticide environment 20232023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dinotefuran15 % Flumethrin0.9 %
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Solano Ltd · Israel
Manufacturer (register)
Solano Ltd, Israel
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 891, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 28 May 2028
Veterinary (National Food Agency)
In the register: სოლტიფ ჰოუმი - დასაწვეთებელი ხსნარი პატარა ზომის ძაღლებისათვის 7-15 კგ (Small)
№ 236-11
Verified on: 22 Oct 2026
Controlled in Georgia
Unknown

Soltif Home 15%/0.9%, Spot-on

3 ml spot-on for dogs 15-25 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
4.9/10
Weak evidence support
vetman assessment

Soltif Home

15%/0.9%, 3 ml spot-on for dogs 15-25 kg
Assessed clinical scopeDog · Labelled monthly topical control of fleas and ticks in dogs within the exact presentation weight band · On the skin
Care settingVeterinary-selected home spot-on use after parasite and patient assessment, with response review when infestation persists
vetman score 4.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 239-11 · Verified on 22 Oct 2026

A locally registered dog-only spot-on with convenient monthly use, but no independent exact-product efficacy study or transparent public dossier. It is a weak-evidence option that should be used only in the exact weight band, with response reassessment and strict protection of cats from direct or wet-coat exposure.

Regulatory and scientific credibility5.5/10

The exact presentation is actively registered in Georgia and current manufacturer material verifies the formulation, weight band and monthly label. However, no regulator-hosted SPC, EMA/FDA-style public assessment or transparent full dossier for this exact dinotefuran/flumethrin spot-on was found.

Clinical efficacy3.5/10

The manufacturer claims 30-day flea and tick protection, but no independent controlled study of this exact 15% dinotefuran plus 0.9% flumethrin spot-on was found. Studies and guidelines support the individual actives or different collars and combinations; they do not validate this formulation, dose distribution or every claim.

Safety and tolerability4.5/10

Dog tolerability data for the exact formulation and repeated use are not publicly available. Pyrethroids generally have a wider margin in dogs than cats, but local and neurologic reactions and ingestion remain possible; a retrospective feline toxicosis series specifically included two Soltif exposures, making species separation essential.

Clinical practicality7.0/10

A whole monthly weight-banded pipette is simple to apply. Correct weight selection, direct placement on dry intact skin where the dog cannot lick, separation from other animals until dry and the 72-hour bathing restriction remain meaningful adherence requirements.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Dog-only product: never apply to a cat. Keep cats from grooming or contacting the treated dog until the application site is completely dry; Soltif exposure has been recorded in hospitalised feline pyrethroid-toxicosis cases.
  • Do not use in puppies younger than 8 weeks or in an animal with known hypersensitivity to an ingredient.
  • Weigh the dog and use only the presentation matching its labelled weight band; boundary weights require deliberate selection rather than estimation.
  • Apply the entire pipette directly to dry intact skin between the shoulder blades where the dog cannot lick. Separate treated animals until dry.
  • Monitor for local irritation, salivation, vomiting, depression, ataxia, tremor, twitching or seizures. If exposure or neurologic signs occur, prevent further licking, wash off when appropriate and seek urgent veterinary advice.
  • Do not layer with another flea/tick pesticide unless a veterinarian has reviewed the active ingredients, intervals and cumulative neurotoxicity.
  • Do not bathe or shampoo the dog for 72 hours after application. Frequent water exposure may reduce topical persistence; reassess rather than shortening the interval without evidence.
  • No independent controlled trial of the exact 15% dinotefuran plus 0.9% flumethrin spot-on was found. Ingredient and other-formulation studies cannot establish this product’s full 30-day performance.
  • Ectoparasiticides may harm aquatic organisms. Prevent the product, empty pipette and recently treated dog from contaminating surface water; dispose of packaging responsibly.
Assessment sources
  1. Solano Soltif Home2026
  2. Georgia NFA register 20262026
  3. ESCCAP ectoparasite guideline2024
  4. CAPC flea guideline2026
  5. EMA Vectra 3D EPAR2024
  6. Comparative ectoparasiticide study2012
  7. Feline pyrethroid toxicosis2020
  8. EMA ectoparasiticide environment 20232023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dinotefuran15 % Flumethrin0.9 %
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Solano Ltd · Israel
Manufacturer (register)
Solano Ltd, Israel
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 894, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 28 May 2028
Veterinary (National Food Agency)
In the register: სოლტიფ ჰოუმი - დასაწვეთებელი ხსნარი საშუალო ზომის ძაღლებისათვის 15-25 კგ (Medium)
№ 239-11
Verified on: 22 Oct 2026
Controlled in Georgia
Unknown

Soltif Home 15%/0.9%, Spot-on

4.8 ml spot-on for dogs over 25 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
4.6/10
Weak evidence support
vetman assessment

Soltif Home

15%/0.9%, 4.8 ml spot-on for dogs over 25 kg
Assessed clinical scopeDog · Labelled monthly topical control of fleas and ticks in dogs within the exact presentation weight band · On the skin
Care settingVeterinary-selected home spot-on use after parasite and patient assessment, with response review when infestation persists
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 213-11 · Verified on 22 Oct 2026

A locally registered dog-only spot-on with convenient monthly use, but no independent exact-product efficacy study or transparent public dossier. The unbounded over-25-kg presentation adds dose uncertainty; protect cats from direct application and contact with the wet treatment site.

Regulatory and scientific credibility5.5/10

The exact presentation is actively registered in Georgia and current manufacturer material verifies the formulation, weight band and monthly label. However, no regulator-hosted SPC, EMA/FDA-style public assessment or transparent full dossier for this exact dinotefuran/flumethrin spot-on was found.

Clinical efficacy3.5/10

The manufacturer claims 30-day flea and tick protection, but no independent controlled study of this exact 15% dinotefuran plus 0.9% flumethrin spot-on was found. Studies and guidelines support the individual actives or different collars and combinations; they do not validate this formulation, dose distribution or every claim.

Safety and tolerability4.5/10

Dog tolerability data for the exact formulation and repeated use are not publicly available. Pyrethroids generally have a wider margin in dogs than cats, but local and neurologic reactions and ingestion remain possible; a retrospective feline toxicosis series specifically included two Soltif exposures, making species separation essential.

Clinical practicality5.0/10

A whole monthly pipette is simple to apply, but the largest label band supplies one fixed 4.8 ml pipette to every dog over 25 kg without a stated upper weight limit. Weight verification, skin placement, prevention of licking and 72-hour bathing restriction remain important, and very large dogs require veterinary judgement rather than automatic extrapolation.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Dog-only product: never apply to a cat. Keep cats from grooming or contacting the treated dog until the application site is completely dry; Soltif exposure has been recorded in hospitalised feline pyrethroid-toxicosis cases.
  • Do not use in puppies younger than 8 weeks or in an animal with known hypersensitivity to an ingredient.
  • The 4.8 ml label is open-ended above 25 kg. Confirm the intended dose in very large dogs; do not add or combine pipettes without veterinary direction.
  • Apply the entire pipette directly to dry intact skin between the shoulder blades where the dog cannot lick. Separate treated animals until dry.
  • Monitor for local irritation, salivation, vomiting, depression, ataxia, tremor, twitching or seizures. If exposure or neurologic signs occur, prevent further licking, wash off when appropriate and seek urgent veterinary advice.
  • Do not layer with another flea/tick pesticide unless a veterinarian has reviewed the active ingredients, intervals and cumulative neurotoxicity.
  • Do not bathe or shampoo the dog for 72 hours after application. Frequent water exposure may reduce topical persistence; reassess rather than shortening the interval without evidence.
  • No independent controlled trial of the exact 15% dinotefuran plus 0.9% flumethrin spot-on was found. Ingredient and other-formulation studies cannot establish this product’s full 30-day performance.
  • Ectoparasiticides may harm aquatic organisms. Prevent the product, empty pipette and recently treated dog from contaminating surface water; dispose of packaging responsibly.
Assessment sources
  1. Solano Soltif Home2026
  2. Georgia NFA register 20262026
  3. ESCCAP ectoparasite guideline2024
  4. CAPC flea guideline2026
  5. EMA Vectra 3D EPAR2024
  6. Comparative ectoparasiticide study2012
  7. Feline pyrethroid toxicosis2020
  8. EMA ectoparasiticide environment 20232023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dinotefuran15 % Flumethrin0.9 %
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Solano Ltd · Israel
Manufacturer (register)
Solano Ltd, Israel
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 881, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 28 May 2029
Veterinary (National Food Agency)
In the register: სოლტიფ ჰოუმი - დასაწვეთებელი ხსნარი დიდი ზომის ძაღლებისათვის >25კგ.
№ 213-11
Verified on: 22 Oct 2026
Controlled in Georgia
Unknown

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗